Otonomy Enrolls First Pediatric Patient In Phase-2 Clinical Trial Of AuriPro

(RTTNews) - Otonomy, Inc. (OTIC), a clinical-stage biopharmaceutical company, Thursday announced the enrollment of the first patients in a Phase 2 clinical trial evaluating AuriPro for the treatment of pediatric patients with acute otitis media with tympanostomy tubes or AOMT.

The one-month, prospective, multicenter, open-label Phase 2 clinical trial will enroll 30 patients, aged 6 months to 17 years old, in the United States.

The company has submitted a New Drug Application or NDA to the U.S. Food and Drug Administration, as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement surgery.